Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

MLA

Yi-Long Wu, et al. Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. May 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....26c01e965a7a4751400c9130eefc53d8&authtype=sso&custid=ns315887.

APA

Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, Sang Won Shin, Shun Lu, Ying Cheng, Ross Andrew Soo, Dong-Wan Kim, Jianying Zhou, Te-Chun Hsia, Azura Rozila Ahmad, & Chong Kin Liam. (2023). Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

Chicago

Yi-Long Wu, Andreas Johne, Rolf Bruns, Karin Berghoff, Jun Zhao, Yiping Zhang, James Chih-Hsin Yang, et al. 2023. “Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis,” May. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....26c01e965a7a4751400c9130eefc53d8&authtype=sso&custid=ns315887.